Figure 1From: Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]Study Design. The patient flow during the entire 52-week period is illustrated. The efficacy and safety evaluation for this report is based on data from the 46-week active-comparator controlled period.Back to article page